📊 Evidence-Based Reference
N-Terface
Winfield Laboratories
Summary: The n-terface is a nonadherent wound dressing used primarily in wound care management. Key evidence highlights its effectiveness in reducing postoperative pain and promoting rapid healing.
FDA Clearance Information
Pathway ?
510(k)
Number ?
K973538 ↗
Decision Date ?
December 16, 1997
Product Code ?
MGP
Device Class ?
—
Evidence ?
0 studies
The n-terface was cleared through the FDA 510k pathway on December 16, 1997, by Winfield Laboratories. It is classified under product code MGP with no specific regulatory class.
What It Is
The n-terface is a nonadherent wound dressing designed to facilitate wound healing by providing a protective barrier while allowing for moisture retention. It is intended for use in various wound care scenarios, including post-surgical applications.
FDA-Cleared Indications
- Management of wounds where a nonadherent protective dressing is needed.
- Use as a wound-contact layer to protect the wound surface while allowing moisture retention.
- Use in postoperative and other wound-care settings according to the product labeling.
Clinical Applications
- Postoperative wound dressing and protection.
- Wound care after laser skin resurfacing.
- Management of infected soft-tissue wounds as part of an overall wound-care plan.
- Protection of the wound surface during dressing changes.
Evidence Summary
The available literature includes three studies ranging from 1990 to 2017, encompassing various study designs such as RCTs and case series. These studies explore the efficacy and safety of the n-terface in different clinical settings.
Reported Outcomes
Published studies report that the n-terface dressing is associated with low postoperative pain, rapid healing, and excellent wound bed visualization. It has been effective in both open and closed wound management, particularly after laser skin resurfacing.
Safety Profile
Reported complications include minimal adverse events, with studies noting the absence of crust formation and painless dressing removal. The nonadherent nature of the dressing contributes to its favorable safety profile.
Evidence Limitations
The evidence is limited by the small number of studies and the lack of large-scale randomized controlled trials. Further research is needed to explore long-term outcomes and compare efficacy with other wound dressings.
Practical Considerations
- Use the product size and configuration that fully covers the wound without extending unnecessarily onto intact skin.
- The dressing should be applied to a cleaned wound according to the product instructions and covered with an appropriate secondary dressing when needed.
- Assess the wound regularly for infection, drainage, skin irritation, or delayed healing; the dressing does not replace antimicrobial treatment, debridement, or other indicated care.
- MRI safety information is not established in the provided FDA record. Confirm the composition and labeling before MRI, particularly if the dressing or packaging contains metallic components.
- Do not use when the patient has a known sensitivity to the dressing material or when the product is damaged, contaminated, or past its expiration date.
Frequently Asked Questions
What are the clinical indications for n-terface?
The n-terface is indicated for use in wound care management, particularly in post-surgical and laser skin resurfacing scenarios.
What outcomes have been reported in clinical studies?
Studies have reported low postoperative pain, rapid healing, and excellent wound bed visualization with the use of n-terface.
What complications have been reported?
Reported complications include minimal adverse events, with studies highlighting the absence of crust formation and painless dressing removal.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.